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ABSTRACT 
 
Dopamine (DA) neurons of the ventral tegmental area (VTA) are critical for decision-
making and motivation and have also been implicated in the development of addictive 
behaviors. The activity of these neurons and the subsequent changes in DA 
concentrations in the target regions of the VTA are strictly regulated by both 
excitatory and inhibitory inputs. Among those inhibitory inputs, GABAergic 
transmission is mediated by phasic and tonic currents generated through different 
GABAA receptor subtypes. Although the phasic currents arising through the activation 
of synaptic GABAA receptors have been well described, much less is known about 
extrasynaptic GABAA receptors mediating tonic currents and modulating neuronal 
activity in the VTA.  
Here, pharmacologically selective receptor modulators, transgenic mouse 
models and brain slice electrophysiology were all exploited to probe the role of 
extrasynaptic GABAA receptors in mediating neuroplasticity in VTA DA neurons. 
Even though they possess distinct molecular sites of action, gaboxadol (THIP) and 
ganaxalone (GAN) enhanced tonic inhibition by selective targeting of the 
extrasynaptic δ subunit-containing GABAA receptors located on VTA GABA 
neurons. The tonic inhibition induced in these neurons appeared to be sufficient to 
disinhibit DA neurons and induce persistent neuroplasticity in the glutamate synapses 
on VTA DA neurons, which resulted from insertion of new GluA2 subunit-lacking 
AMPA receptors into the synapses. 
Screening of reward-related behaviors associated with VTA DA activity 
revealed that THIP failed to induce any reinforcement during self-administration 
either in mice or baboons. Moreover, both THIP and GAN produced conditioned 
place aversion in mice. The study performed in δ subunit-knockout mice further 
supported the proposal that tonic inhibition of the VTA GABA neurons contributes to 
conditioned aversive behavior and THIP- and GAN-induced neuroplasticity. 
The c-Fos mapping of brain regions, which could take part in THIP-induced 
aversive behavioral effects and/or neuroplasticity on VTA DA neurons, revealed the 
bed nucleus of stria terminalis (BNST), a part of the so-called extended amygdala 
circuitry, as a possible participant in mediating the aforementioned THIP-induced 
aversive effects. 
In summary, these studies demonstrate that tonic inhibition mediated by δ 
subunit-containing GABAA receptors appears to be a significant component of the 
inhibition in the VTA, and thus important for the control of motivated behavior.  
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ABBREVIATIONS 
 
 
AMPA  
  
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid  
AA29504  2-amino-4-(2,4,6-trimethylbenzylamino)-phenyl-carbamic acid ethyl 
ester  
BBB   Blood brain barrier 
BNST  Bed nucleus of stria terminalis 
BLA  Basolateral complex of the amygdala 
CA1  Cornu ammonis 1 of the hippocampus 
CA3  Cornu ammonis 3 of the hippocampus 
CeA  Central nucleus of the amygdala 
c-Fos  Cellular oncogene Fos 
DA   Dopamine 
D-AP5  D-2-amino-5-phosphonopentanoic acid; NMDA receptor antagonist 
δ-KO  GABAA receptor δ-subunit knockout mouse line 
δ-WT  GABAA receptor δ-subunit wild type mouse line 
DS1  4-chloro-N-[6,8-dibromo-2-(2-thienyl) imidazo [1,2-a] pyridine-3-yl] 
benzamide 
DS2  4-chloro-N-[2-(2-thienyl) imidazo [1,2-a] pyridine-3-yl benzamide 
JM-11-43A Dihydropyrimidinone 
EGFP   Enhanced green fluorescent protein 
EPSC  Excitatory postsynaptic current 
GABAA  γ-aminobutyric acid type A (receptor) 
GAN   3α-hydroxy-3β-methyl-5α-pregnan-20-one, ganaxolone 
IPSC  Inhibitory postsynaptic current 
LDT  Laterodorsal tegmentum 
LTD  Long-term depression 
LTP  Long-term potentiation 
mEPSC   Miniature excitatory postsynaptic current 
NAcc  Nucleus accumbens 
NMDA   N-methyl-D-aspartate 
PFC   Prefrontal cortex 
RMTg   Rostromedial tegmental nucleus  
PVA  Paraventricular thalamic nucleus 
sIPSC  Spontaneous inhibitory postsynaptic current 
Th  Tyrosine hydroxylase 
THIP   4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol, gaboxadol 
VTA   Ventral tegmental area 
vPAG  Ventrolateral periaqueductal grey  
5α-THDOC 5α-tetrahydrodeoxycorticosterone  
5α3α-THPROG 5α3α-tetrahydroprogesterone, allopregnanolone 
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GLOSSARY OF TERMS 
 
 
Phasic GABAergic transmission refers to synaptic-type of neuronal transmission 
generated by the rapid, transient activation of synaptic ionotropic GABAA receptors 
by presynaptic GABA release. The phasic transmission is present in all brain areas, 
and mediates most of the fast-acting inhibitory neurotransmission. 
 
Tonic GABAergic transmission refers to the nonsynaptic-type of neuronal 
transmission generated by the persistent activation of specialized classes of ionotropic 
GABAA receptors residing outside of the synaptic cleft. These “extrasynaptic” 
GABAA receptors can detect low ambient GABA levels. Tonic transmission is 
present only in selected brain regions, especially in the cerebellum and thalamus, and 
it participates in controlling neuronal excitability.??? 
 
Phasic DAergic transmission refers to the burst spike firing pattern, which often 
occurs in response to behaviorally relevant stimuli. This burst spike activity triggers a 
high amplitude (μM to mM levels), ?transient phasic DA release within the target 
areas.?? 
 
Tonic DAergic transmission refers to constantly occurring ?baseline firing, which is 
driven by pacemaker-like membrane currents of DA neurons. Tonic activity keeps up 
extracellular baseline DA levels (nM ?levels) within the target areas.? 
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1 INTRODUCTION  
 
 
We are continually bombarded by different stimuli, theoretically, all could be acted 
upon, but in fact only a few become the targets of behavior. The mesolimbic 
dopamine (DA) system is one of the brain systems whose function is to alert the 
organism and help it to “prioritize” one stimulus over another to support its well-
being and adjustment to the environment. Drug addiction is a chronic disorder 
associated with loss of control over drug seeking and drug intake. Drugs of abuse 
converge on the DA system to change the rules by “re-prioritizing” drug-associated 
stimuli so that they even are placed ahead of those essential for survival. 
Once the effects of drugs of abuse have been experienced, they induce long-
term synaptic plasticity in the excitatory transmission in midbrain DA neurons in 
ventral tegmental area (VTA). Although these adaptations are transient, they are 
believed to reflect “memory trace” left by drugs of abuse after they have disappeared 
from the brain, and can lead to a rearrangement of neural circuitry involving many 
other neuromodulator systems.  
Stringent control of VTA activity by the main brain inhibitory neurotransmitter 
system, using γ-aminobutyric acid (GABA) as the transmitter, ensures its normal 
functioning. The other side of the coin is that, the DA system also becomes a target 
for many GABAergic drugs. Indeed, benzodiazepines, anesthetics and alcohol all 
selectively or less selectively act on GABA type A (GABAA) receptors. It is well 
known that the long-term use of these drugs and alcohol may result in the 
development of addicition, tolerance and dependence.  
According to the latest European reports, 15.5 million people suffer from drug 
and alcohol addiction and the total cost related to this disorder exceeded over 60 
billion euros (Olesen et al., 2012). Thus, the physiological and pharmacological 
consequences of addictive drug use are of major research interest. This serves us the 
impetus for the extensive research efforts being made to seek for new drugs which 
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would possess more selective actions with greater efficacy and fewer side effects. 
Extrasynaptic GABAA receptors can be considered as a potent new therapeutical 
target for several central nervous system (CNS) disorders. These special types of 
inhibitory receptors are expressed at relatively low levels throughout the brain in 
selected populations of neurons, and it is known that they can be selectively 
modulated by pharmacological agents. 
The present study explored the modulation of activity of VTA DA neurons and 
synaptic plasticity by selective modulators of extrasynaptic GABAA receptors. Then 
the significance of synaptic adaptations induced by these compounds was evaluated in 
several reward-related tasks and models to reveal their possible addictive or anti-
addictive properties. 
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2  REVIEW OF  
THE LITERATURE 
 
 
 
2.1  THE GABAA RECEPTOR SYSTEM 
 
γ-Aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the brain. 
This neurotransmitter exerts its actions by interacting with specialized membrane 
proteins, the GABA receptors. The fast-acting inhibitory effects of GABA are 
performed by GABAA receptors (Naik et al., 1976). 
GABAA receptors belong to the “cys-loop” superfamily of ligand-gated ion 
channels (Leite and Cascio, 2001). They exist as heteropentameric structures where 
five subunits are arranged around a central pore. When GABA (the endogenous 
ligand of GABAA receptor) binds to and triggers conformational change in the 
receptor complex, this leads to opening of the pore. This, in turn, allows Cl− and 
HCO3− ions to pass down their electrochemical gradients, and induce 
hyperpolarization of cell. This hyperpolarization creates an inhibitory effect on 
neurotransmission by decreasing the probability of generating an action potential. In 
some instances, e.g. in early neuronal development, they can be depolarizing because 
the intracellular Cl− concentration is high (Kaila et al., 1997; Rivera et al., 1999). 
Thus, depolarization creates an excitatory effect on neuronal neurotransmission. 
GABAA receptors display widespread expression in all brain regions (Lüddens 
and Korpi, 1995), but they exhibit unique heterogeneity in terms of structure, 
function, distribution, and pharmacological profile (Uusi-Oukari and Korpi, 2010). 
This heterogeneity results from the large number of subunits, which can be present in 
a GABAA receptor. To date, 19 subunits have been cloned (Barnard et al., 1998). 
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According to an analysis of the homology, they can be subdivided into 8 classes: α1-
6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3 (Olsen and Sieghart, 2009). Additional heterogeneity 
occurs via alternative splicing of exons during gene expression (Kirkness and Fraser, 
1993; Korpi et al., 1994; Jin et al., 2004).  
It is noteworthy to mention that a comparative analysis of the GABAA receptor 
genes between the species has not revealed any new GABAA receptor subunits in the 
human genome (Simon et al., 2004). Accordingly, the human the GABAA receptor 
genes show a basic pattern of 9 coding exons. Additional noncoding exons have been 
discovered for certain subunits, and these may exert regulatory functions (Simon et 
al., 2004). This kind of high level of GABAA receptor homology makes research in 
rodents highly translatable to the human condition, which can be important in drug 
discovery in the GABAA receptor field. 
The GABAA receptor is usually composed of two α subunits, two β subunits 
and one γ or δ subunit (McKernan and Whiting, 1996). If one considers the γ-
containing receptors, then α1β2γ2, α2β2/3γ2 and α3βnγ2/γ3 are the most abundant 
combinations. They are present in almost all brain areas, and together they constitute 
about 75 % of the total GABAA receptor repertoire (Fritschy et al., 1992; Laurie et al., 
1992). As a general rule, γ-containing receptors are preferentially located into 
synapses (Fritschy et al., 1992; Peng et al., 2002). Other subtypes consist of mainly 
α4βδ and α6βδ compositions. These exhibit a more selective distribution in brain, but 
they account for only 5% of total receptor repertoire and exclusively located out of 
synapse. Despite the low abundance of δ-containing receptors, they exert a major 
impact on the functioning of neuronal network.  
2.1.1  Diversity of inhibition through GABAA receptors 
The GABAergic cells regulate the activity of neuronal networks by acting through 
diverse sets of inhibitory processes, the complexity of which is supplemented by the 
wide variety of interneurons and their circuits (Klausberger and Somogyi, 2008). 
Moreover, the intrinsic properties of GABAA receptors and their subcellular 
localization can develop several forms of inhibition (Mody and Pearce, 2004).  
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Figure 1. Neuronal inhibition mediated via GABAA receptors contains phasic and tonic components.  
A. Neurotransmitter GABA, after release from GABAergic interneuron, binds to and activates synaptic 
and extrasynaptic GABAA receptors promoting phasic and tonic components of inhibition, respectively. 
The astrocytes are involved in several processes including GABA uptake and release, regulation of 
anion concentration in the extracellular space. B. Whole-cell patch-clamp recording of GABAA receptor-
mediated currents shows phasic and tonic currents. Phasic current is represented by the phasic inward 
inhibitory post-synaptic currents (IPSCs). It can be inhibited by treatment with a GABAA receptor 
antagonist (e.g. gabazine). The antagonist also blocks the tonic current, which results in an outward 
shift of the holding current. C. GABAA receptors contain 5 membrane-crossing subunits that are 
arranged to form an intrinsic anion-conducting channel. Most synaptic receptors comprise α, β and γ2, 
whereas extrasynaptic comprise α, β and δ subunits. 
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The two main forms of inhibition are mediated by GABAA receptors (Figure 
1A). Phasic (also called synaptic) inhibition is generated by “phasic” inhibitory post-
synaptic currents (IPSCs) following activation of γ-containing GABAA receptors 
(Farrant and Nusser, 2005). In contrast to phasic IPSCs, tonic inhibition results from a 
persistent low-amplitude current capable of additional modulation of action potential 
firing (Figure 1B) (Walker and Kullmann, 2012). 
Tonic inhibition results from activation of δ-containing GABAA receptors 
which are located outside of synapses. The hallmarks of extrasynaptic and 
perisynaptic GABAA receptors are their high affinity for GABA and slow 
desensitization (Figure 1C) (Farrant and Nusser, 2005), but also see (Bright et al., 
2011). These extrasynaptic δ-containing GABAA receptors will be the central topic of 
this thesis. 
2.1.2  GABAA receptors underlying tonic currents 
Extrasynaptic GABAA receptors mediating tonic currents are different from those 
contributing to the peak synaptic currents (Table 1). They are developmentally 
regulated and exhibit a cell-type specific distribution (Farrant and Nusser, 2005; 
Walker and Kullmann, 2012).  
Cerebellar granule cells probably are the best example of a brain region 
expressing large numbers of GABAA receptors contributing to tonic inhibition 
(Kaneda et al., 1995). Lately, tonic inhibition also has been found in the hippocampal 
CA1 interneurons (Semyanov et al., 2003), granule cells of the dentate gyrus (Nusser 
and Mody, 2002), interneurons of the dentate molecular layer (Glykys et al., 2007), 
thalamocortical relay neurons (Porcello et al., 2003), pyramidal cells in the neocortex 
(Vardya et al., 2008), basolateral (BLA) and lateral (LA) nuclei of the amygdala 
(Marowsky et al., 2012). 
Several GABAA receptor subtypes have been proposed to mediate tonic 
inhibition. In particular, α6βxδ mediate tonic currents in cerebellar granule cells 
(Brickley et al., 1996), α1βxδ receptors in hippocampal interneurons (Glykys et al., 
2007), α4βxδ receptors in dentate granule cells (Nusser and Mody, 2002), and 
thalamocortical neurons (Belelli et al., 2005). Other receptor subtypes may also 
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mediate tonic currents, including the ɛ-containing receptors in hypothalamic neurons 
(Wagner et al., 2005) and α5βxγx receptors in CA1 pyramidal cells (Caraiscos et al., 
2004). Nonetheless α5βxγx receptors in contrast to the δ-containing receptors have a 
very restricted distribution within hippocampus, and they are not exclusively located 
extrasynaptically (Serwanski et al., 2006).  
There is growing evidence that other GABAA receptors can be expressed 
extrasynaptically and are able to mediate a tonic current (Mody and Pearce, 2004; 
Walker and Kullmann, 2012). Even within a single neuron there may be several 
subtypes exhibiting different subunits and consequently receptors with different 
affinities for GABA may contribute to the generation of tonic current (Prenosil et al., 
2006). This heterogeneity might be needed to extend the range of extracellular GABA 
concentrations that can modulate neuronal excitability and increase the number of 
potential modulators (Walker and Kullmann, 2012). 
Table 1. Hallmarks of synaptic and extrasynaptic GABAA receptors Modified from (Reddy, 2013). 
 
Synaptic GABAA receptor Extrasynaptic GABAA receptor 
Mediation of phasic currents Mediation of tonic currents 
Pentameric ligand-gated anion channels Pentameric ligand-gated anion channels 
Presence of γ2 subunit Presence of δ, α5 subunits 
Synaptic localization Perisynaptic, extrasynaptic localization 
Low GABA affinity High GABA affinity 
Not blocked by low Zn2+ Blocked by low Zn2+ 
Wide distribution in the brain Selective distribution in brain region 
2.1.3  Origin of tonic currents  
In evolutionary terms, GABA signaling was already found in invertebrates and 
bacteria (Lummis et al., 1991; Belelli et al., 1996). Subsequently sequence analysis 
has revealed that this system has been conserved throughout the course of evolution 
(Martyniuk et al., 2007; Ryan and Grant, 2009). Interestingly, it is even possible that 
GABA receptors preceded the origin of synapses and excitatory ionotropic glutamate 
receptors (Perovic et al., 1999; Ryan and Grant, 2009).  
The gene coding the δ subunit is positioned separately from the rest of subunits 
on chromosome 4 and 1 (1p36.3) in mice and humans, respectively (Sommer et al., 
1990; Windpassinger et al., 2002). The phylogenetic studies of Ortells and Lunt 
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suggested that δ subunit is the most primitive subunit within GABAA receptor family 
(Ortells and Lunt, 1995). In line with this view, pharmacological studies in primitive 
invertebrates (e.g. Hydra Vulgaris) with the simplest nervous system have revealed 
that they possess GABAA receptors which are sensitive to muscimol and 
neurosteroids, modulators of extrasynaptic receptors (Concas et al., 1998). It is 
believed that these early developmental forms of GABA signaling may play a role in 
controlling of feeding, as well as participating in the neuronal differentiation 
(LoTurco et al., 1995; Concas et al., 1998; Brickley and Mody, 2012). 
2.1.4  The mechanism of tonic inhibition  
The tonic inhibition (or excitation) remains as a form of signaling which is not time-
locked to presynaptic action potentials. Thus, the tonic signaling profoundly 
modulates the input-output relationships of the neurons. Notably, tonic currents can 
sometimes be paradoxically excitatory, either by depolarizing neurons or via a 
network effect (Walker and Kullmann, 2012).  
The mechanism of tonic inhibition needs to be clarified even though numerous 
studies have tried to address this issue. There are three hypotheses which have been 
proposed to explain this action: 
1. Tonic inhibition results from summation of overlapping miniature IPSCs 
(Salin and Prince, 1996). Demonstration of distinct pharmacological properties of 
tonic current and miniature IPSCs has rejected this hypothesis. In particular, in 
hippocampal cells the GABAA receptor antagonist, gabazine, blocked miniature 
IPSCs, but not tonic current (Bai et al., 2001).  
2. Tonic inhibition results from activation of high-affinity extrasynaptic 
GABAA receptors by GABA, which may have spilled-over from neighboring 
synapses (Brickley et al., 1996; Rossi et al., 2003). A recent re-examination 
challenged this assumption and proposed that spillover and tonic currents are separate 
phenomena, reflecting the activation of distinct GABAA receptor populations in 
thalamus and cerebellum (Bright et al., 2011). Indeed, the source of ambient GABA 
can have a different origin depending on cell type, anatomy of synapse etc. It has been 
suggested to originate from astrocytes (Liu et al., 2000), reversed transport of GABA 
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by its transporter (Gaspary et al., 1998; Wu et al., 2006), by a reduced activity of 
GABA-transaminase (Overstreet and Westbrook, 2001), by non-vesicular GABA 
exocytosis (Rossi et al., 2003), as well as from glial cells by permeation through the 
Bestrophin 1 anion channel (Lee et al., 2010). 
3. Tonic inhibition results from spontaneously opening GABAA channels 
(Birnir et al., 2000; Birnir et al., 2000). In other words, the authors hypothesized that 
there is neurotransmitter-independent mechanism of tonic inhibition in hippocampal 
CA1. However, this hypothesis does not explain several issues. First, concentration-
dependent enhancement of tonic current was observed in response to GABA 
(Overstreet and Westbrook, 2001). Second, this hypothesis also is at odds with the 
well-known observation that GABAA receptor antagonists, which compete with 
GABA for the same binding site, block tonic inhibition (Mody and Pearce, 2004; 
Farrant and Nusser, 2005). Moreover, these antagonists could exert an intrinsic effect 
without competing with GABA (Korpi et al., 1996). All these aforementioned 
findings seem to indicate that the tonic current may consist of two components: 
neurotransmitter GABA-dependent and GABA-independent currents. 
2.1.5  Modulators of extrasynaptic GABAA receptors 
Several mechanisms have been postulated to modulate tonic inhibition, e.g. alterations 
in receptor expression, changes in endogenous neurosteroids, variations in ambient 
GABA concentrations, and numerous neuroactive drugs (Walker and Kullmann, 
2012). 
? Endogeneous modulators of extrasynaptic GABAA receptors 
In addition to the natural neurotransmitter GABA, endogenous neurosteroids and their 
metabolites such as 5α-tetrahydrodeoxycorticosterone (5α-THDOC) and 5α3α-
tetrahydroprogesterone (5α3α-THPROG, also known as allopregnanolone) are the 
most potent positive modulators of GABAA receptors (Lambert et al., 2009). 
Neurosteroids are synthesized de novo by some neurons and glia (Robel et al., 1995; 
Melcangi et al., 2001). They act on the GABAA receptor at distinct sites not 
overlapping with the binding sites of GABA, benzodiazepines, or barbiturates (Gee et 
al, 1995). Moreover, neurosteroids display broad-spectrum modulatory effects on 
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several GABAA receptors (Lambert et al., 2009), they exhibit particular sensitivity to 
extrasynaptic α4βδ, α6βδ receptors (Wohlfarth et al., 2002; Spigelman et al., 2003). 
Furthermore, their effects on GABAA receptors have been postulated to involve 
signaling via protein kinase C activity (Fancsik et al., 2000), and to influence GABAA 
receptor subunit expression (Shen et al., 2005; Maguire et al., 2005; Maguire and 
Mody, 2007). Administration of neurosteroids evokes anxiolytic, sedative, analgesic, 
and anticonvulsive effects (Lambert et al., 2009). 
? Exogenious modulators of extrasynaptic GABAA receptors 
Direct GABAmimetic agent muscimol, is a psychoactive ingredient of the mushroom 
Amanita muscaria, activates all GABAA receptors by targeting binding site of GABA 
(Figure 2) (Krogsgaard-Larsen et al., 1979; Korpi et al., 2002). Recently, 
electrophysiological studies with recombinant GABAA receptors and high-affinity 
[3H]muscimol binding have revealed that muscimol has a preferential action on 
α4β3δ and α6βδ extrasynaptic GABAA receptors (Storustovu and Ebert, 2006; 
Chandra et al., 2010). Despite the fact that muscimol has been extensively studied 
over decades, its poor blood brain barrier (BBB) penetration property did not allow its 
use in clinic (Krogsgaard-Larsen et al., 2004). 
THIP (4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol, also known as gaboxadol) is a 
muscimol analogue with better bioavailability (Figure 2) (Krogsgaard-Larsen et al., 
1979; Brown et al., 2002; Storustovu and Ebert, 2006). THIP acts as a partial agonist 
at the synaptic α1-containing receptors, full agonist at α2- containing receptors, and as 
a superagonist at the extrasynaptic GABAA receptors (Ebert et al., 1994; Ebert et al., 
1997; Wafford and Ebert, 2006). Indeed, THIP exhibits a 10-fold higher potency for 
the α4β3δ and α6β3δ than for synaptic receptors. Moreover, THIP induces a tonic 
current via these δ receptors which is double that which can be achieved by GABA 
(Brown et al., 2002; Saarelainen et al., 2008; Meera et al., 2011), and GABA can act 
as an antagonist by reducing these “superagonist” THIP-effects. 
THIP appears mainly to exert its action in the midbrain and forebrain (Krogsgaard-
Larsen et al., 2004). Its administration leads to sedative, analgesic and ataxic effects, 
which were completely abolished in mice lacking either α4 or δ subunits (Chandra et 
al., 2006; Winsky-Sommerer et al., 2007). There are several reports demonstrating 
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that at therapeutical relevant concentrations THIP preferentially acts at extrasynaptic 
receptors, whereas higher concentrations can affect additional subtypes (Boehm et al., 
2006). THIP displayed low tolerance and addiction properties in clinical trials for its 
hypnotic effects (Ebert et al., 2006). However, it was discontinued due to lack of 
efficacy and a higher incidence of psychiatric side effects (see website downloaded in 
November 2013 http://www.drugs.com/news/merck-amp-co-inc-lundbeck-
discontinue-joint-development-program-gaboxadol-investigational-compound-
5660.html).  
DS1 and DS2 compounds from the imidazopyridine family have been recently 
described (Wafford et al., 2009). For example, DS1 is considered to be selective 
agonist of δ-containing GABAA receptors, whereas DS2 is an allosteric enhancer of 
receptor function (Wafford et al., 2009). Importantly, the binding sites for these 
compounds are distinct from currently known sites on GABAA receptor (Wafford et 
al., 2009; Jensen et al., 2013). The current data originate mainly from in vitro 
experiments, as in vivo studies have been complicated so far because of the very poor 
brain penetration of these analogs (Jensen et al., 2013). 
Synthetic neurosteroid ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-one) is the 
3β-methylated synthetic analog of allopregnanolone, which exhibits potent 
anticonvulsant activities (Figure 2) (Carter et al., 1997; Reddy and Rogawski, 2009). 
Since ganaxolone shares the primary neuropharmacological characteristics of 
allopregnanolone (Belelli and Herd, 2003), in this chapter its distinct features will be 
reviewed. First, ganaxolone lacks nuclear steroid hormonal activity, and therefore 
does not exert steroidal side effects (Carter et al., 1997). Second, ganaxolone 
preferentially acts on δ-containing GABAA, then on α1, α2 or α3-containing GABAA 
receptors (Carter et al., 1997; Mihalek et al., 1999; Belelli et al., 2005; Brown et al., 
2002; Fodor et al., 2005). Third, ganaxolone has a rapid onset of action and it is 
quickly metabolized (Nohria and Giller, 2007). Fourth, ganaxolone acting on δ-
containing GABAA receptors exerts anxiolytic and anticonvulsive and anesthetic 
effects in mice (Mihalek et al., 1999). 
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Triaminobenzene compound AA29504 (2-amino-4-(2,4,6-trimethylbenzyl amino) -
phenyl-carbamic acid ethyl ester) has been recently described as a functionally 
positive allosteric modulator of the effects of agonists (GABA and THIP) for α4β3δ 
GABAA receptors. AA29504, over a range of doses, has been reported to penetrate 
readily through the BBB, and its administration results in stress-reducing and 
anxiolytic effects in mice (Hoestgaard-Jensen et al., 2010; Vardya et al., 2012). On 
other hand, AA29504 is an analogue of retigabine, the Kv7 channel opener. 
Therefore, the effects of AA29504 need to be carefully reviewed if one is associating 
its actions exclusively with δ-containing GABAA receptors (Hoestgaard-Jensen et al., 
2010; Vardya et al., 2012).   
Dihydropyrimidinone compound JM-11-43A has been described as a selective 
positive allosteric modulator of α4β3δ GABAA receptors, but as with AA29504 this 
drug appears to exhibit only limited selectivity (Lewis et al., 2010). 
Ethanol acts widely on many types of ion channels and intracellular signalling 
pathways including GABAergic system. Extrasynaptic GABAA receptors also seem 
to agree with this rule (Uusi-Oukari and Korpi, 2010). Several studies have shown 
that low concentrations of ethanol enhance tonic current (Smith et al., 1992; Wallner 
et al., 2003; Hanchar et al., 2004). On the other hand, deletion of the α4 subunit did 
not result in any changes in behavior after acute effects on ethanol (Chandra et al., 
2008), and several groups have failed to detect the low concentration effects of 
ethanol on δ-containing GABAA receptors (Borghese et al., 2006; Korpi et al., 2007; 
Linden et al., 2011). 
Several general anesthetics (isoflurane, etomidate) display broad-spectrum 
modulatory effects on several GABAA receptors, but isoflurane and etomidate exhibit 
a more selective action on extrasynaptic GABAA receptors. In particular, volatile 
anesthetic isoflurane, at its low sedative concentrations (25-85 mM), selectively 
increases tonic conductance targeting extrasynaptic α5β3γ2L in the hippocampus 
(Caraiscos et al., 2004) and α4β2δ GABAA receptors in the thalamus (Chandra et al., 
2006; Jia et al., 2009). Similar to isoflurane, the intravenous anesthetic, etomidate, is 
known to enhance tonic conductance by targeting α4β2/3δ in the neocortex (Brown et 
al., 2002; Drasbek et al., 2007).  
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Figure 2. Schematic representation of the δ-containing GABAA receptor and its associated binding sites 
for its modulators. 
 
The extrasynaptic GABAA receptors contain binding sites for several clinically relevant drugs. A. 
Chemical structures for modulators of the receptor B. GABAmimetic drugs bind to the two GABA-sites 
at the interface between α and β subunits. Anesthetics, neurosteroids, and ethanol bind to distinct sites 
in the membrane-spanning transmembrane regions at the interface between α and β subunits. The 
binding sites for DS1, DS2, AA29504, and JM-11-43A have not been identified. 
2.1.6  Extrasynaptic GABAA receptor as a potential drug target 
 
From the therapeutic perspective, extrasynaptic GABAA receptors are considered as a 
potentially important pharmacological target for several central nervous system 
(CNS)-, and non-CNS-related disorders (Table 2) (Mendu et al., 2011; Brickley and 
Mody, 2012). 
To date, several compounds including THIP and GAN are undergoing clinical 
trials. In particular, the combination of THIP and escitalopram, a selective serotonin 
reuptake inhibitor, was recently tested in a clinical trial (Phase II) for the treatment of 
patients with severe major depressive disorder. Regrettably, after 8 week-treatment 
there was no clinically relevant efficacy difference between a combination of 
escitalopram and THIP compared to escitalopram alone (Kasper et al., 2012).  
Several clinical trials (Phase II) of ganaxolone have been completed for the 
treatment of epilepsy in both infants and adults (Nohria and Giller, 2007; Pieribone et 
al., 2007). In addition, there are several ongoing trials (all in Phase II) for the 
treatment fragile X syndrome, posttraumatic stress disorder, and nicotine dependence 
(see website downloaded in November 2013 www.clinicaltrials.gov).  
18 
 
Table 2. Summary of the implications of extrasynaptic GABAA receptors in human disorders  
 
Implications Findings References 
 
Adult uncontrolled partial-
onset seizures, 
catamenial epilepsy, 
infantile spasms  
 
Deficient of tonic inhibition due to several 
reasons including mutations in the δ 
subunit gene, imbalance of neurosteroids 
 
Mihalek et al., 1999; 
Maguire et al., 
2005; Biagini et al., 
2010; Macdonald et 
al., 2010  
  
Absence epilepsy  
 
 Enhancement of tonic inhibition on 
thalamic relay neurons 
  
Fariello and 
Golden, 1987 
 
Pain (acute nociception 
and central sensitization)  
 
Deficient of tonic inhibition in lamina II 
neurons in spinal cord 
 
Peng et al., 2009;  
Bonin et al., 2011  
 
Post- traumatic stress 
disorder  
 
Deficient of tonic inhibition in 
hippocampus. Decrease in the 
allopregnanolone levels in medial 
prefrontal cortex, hippocampus, and 
basolateral amygdala 
  
Wiltgen et al., 2005; 
Pibiri et al., 2008  
 
Schizophrenia  
 
Disbalance of neurosteroids: increased 
pregnenolone and 
dehydroepiandrosterone levels in 
posterior cingulate and parietal cortex, 
reduced allopregnanolone levels in 
parietal cortex  
 
 Marx et al., 2006  
  
Mood disorders  
(major depressive 
disorder, female stress 
disorders, childhood-
onset mood disorders)  
  
Imbalance of GABAergic signaling. 
Chromosomal 1p36 deletion (or 
dysfunction) associated with moderate to 
severe psychomotor retardation, epilepsy, 
and self-abusive behaviour resulting in 
chromosomal deletion the δ subunit of the 
human GABAA receptors 
  
Windpassinger et 
al., 2002; 
Maguire and Mody, 
2007;  
Smith et al., 2007; 
Feng et al., 2010 
 
Alcoholism  
 
Disbalance of GABAergic signaling 
associated with elevation of endogenous 
neurosteroids, presynaptic release of 
GABA, and dephosphorylation of GABAA 
receptors. Reduction of δ subunit in 
medial shell region of the NAcc reduces 
alcohol intake  
 
Enoch, 2008;  
Rewal et al., 2009; 
Nie et al., 2011  
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Fragile X syndrome 
  
Impaired GABAergic transmission in 
different brain regions in Fmr1 knockout 
mice. Deficits in tonic inhibition might be 
responsible for hypersensitivity to auditory 
stimuli, hyperactivity, exaggerated fear, 
and seizures  
  
Olmos-Serrano et 
al., 2010; 2011 
Heulens et al., 
2012; Conde et al., 
2013  
 
Learning and memory 
enhancement 
 
Partial or full deficiency of α5, and also 
that of δ subunit improved performance in 
associative learning and memory tasks. 
Enhanced tonic inhibition attenuates 
development of LTP in hippocampus  
 
Collinson et al., 
2002; Yee et al., 
2004; 
Shen et al., 2010  
  
Neuroprotection 
  
Reduction α5- and δ-mediated tonic 
inhibition promotes functional recovery 
after stroke 
  
Clarkson et al., 
2010; Santhakumar 
et al., 2010  
  
Type 1 diabetes 
  
Potential role of δ-containing GABAA 
receptors in the decrease of pancreatic 
islet inflammation by inhibiting 
autoreactive T cells 
 
  
Mendu et al., 2011; 
Jin et al., 2013  
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2.2  THE DOPAMINE REWARD SYSTEM 
In 1954, James Olds and Peter Milner of McGill University first described rewarding 
and aversive nuclei in the septal area, when stimulation of those made “rats do 
everything possible to meet or avoid stimulation”, respectively (Olds and Milner, 
1954). Further pharmacological experiments on intracranial self-administration of 
different drugs of abuse within the above brain regions just supported the idea of a 
reward circuit (Wise and Bozarth, 1985; Carlezon and Wise 1996).  
Later, Phillips and Fibiger revealed the crucial role of dopamine (DA) in 
maintaining self-stimulation in the ventral tegmentum, nucleus accumbens (NAcc), 
and medial prefrontal cortex (Phillips and Fibiger, 1978; Grace, 1991). In the 1990’s, 
it was found that a phasic DA release (transient strong relase of DA by action 
potentions burst firing in DA neurons) was associated with different rewarding events 
(Grace, 1991; Schultz et al., 1997). Today, the development of novel state-of-the-art 
techniques (genetic mouse models, novel tracers, optogenetics, etc.) has expanded our 
knowledge by clarifying the neural pathways involved in the processing of reward 
and aversion (Luscher and Malenka, 2011; Jennings et al., 2013; Lammel et al., 
2013). 
It is also important to note that the DA system has received so much attention 
for the last decades due to its contribution to the development of drug addiction. 
Different drugs of abuse (alcohol, psychostimulants, opioids, nicotine etc.) are able to 
dramatically disrupt normal functioning of brain’s reward system (George and Koob 
2010, Volkow et al., 2011; Luscher and Malenka, 2011). Notably, if acute 
administration of drugs of abuse leads to augmentation of DA transmission (Di Chiara 
and Imperato 1988), the chronic drug exposure leads to its reduction in the targeted 
regions (Nestler 2005, Volkow et al., 2011). Moreover, such reduction of DA 
transmission may contribute to the negative emotional symptoms observed between 
drug exposures or upon drug withdrawal (Koob and Le Moal, 2001; Nestler 2005). 
Thus, the mesocorticolimbic DA system may represent an important system in the 
initiation and maintenance of drug addiction. 
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2.2.1  Neurophysiology of reward  
VTA DA neurons transmit DA in two modes, “tonic” and “phasic” by firing action 
potentials in different patterns (Grace, 1991; Grace et al., 2007). In their tonic firing 
mode (2–10 Hz), VTA DA neurons maintain a baseline level of extracellular DA (5-
20 nM) that is vital for the normal functioning of neural circuits (Parsons and Justice, 
1992; Schultz, 2007). In their phasic firing mode (up to 15–30 Hz), DA neurons can 
abruptly change alter their firing rates for hundreds milliseconds, leading to major 
changes in DA concentrations (up to 1 μM) in downstream structures (Garris et al., 
1997; Schultz et al., 1997; Schultz, 2007). 
In 1997 Wolfram Schultz proposed the DA reward prediction error hypothesis. 
According to this hypothesis, the phasic DA responses are induced by many types of 
rewards and cues that predict reward, when the reward value is higher than expected, 
but they are inhibited when the value is lower (Schultz et al., 1997). In fact, this 
hypothesis has been shown to be generally applicable to many species such as 
rodents, primates, and humans (Cohen et al., 2012; D'Ardenne et al., 2008). Further 
studies on primates revealed that only some DA neurons comply with Schultz’s 
hypothesis. It seems unlikely that all DA neurons follow this one rule independently 
of their diverse DA projections, and their functions. Instead, a greater number of DA 
neurons respond to both rewarding and aversive stimuli, in conflict with the 
hypothesis (Matsumoto and Hikosaka, 2009). Many recent elegant 
electrophysiological studies have found that VTA DA neurons exhibit very extensive 
heterogeneous responses to aversive stimuli (Brischoux et al., 2009; Ungless et al., 
2010; Lammel et al., 2011; Wang and Tsien, 2011; Budygin et al., 2012). It is still 
unclear which DA neurons are able to mediate aversion. Schultz has proposed that it 
might be mediated by a small specific DA subpopulation (Schultz, 2013), whereas a 
recent study claimed that almost near equal numbers of DA neurons can be activated 
or inhibited in response to aversive stimulus such as tail pinch (Zweifel et al., 2011). 
One of the possible explanations for these controversial findings might be traced to 
the imprecise identification of DA neurons (discussed below). Thus, some DA 
neurons could be overlooked (e.g. minor DA nuclei) or misinterpreted as being non-
DA neurons (Lammel et al., 2013).  
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2.2.2  Dopamine reward circuits  
DA reward system originates from the ventral tegmental area (VTA), one of the major 
DA nuclei, which sends its main projections to the NAcc (~85% of projections), to 
the amygdala (~50%) and prefrontal cortex (mPFC, ~30%) (Swanson, 1982; Lammel 
et al., 2013).  
Through its projections, the VTA integrates input from many brain regions 
including autonomic, motor, and somatosensory areas (Figure 3) (Watabe-Uchida et 
al., 2012). This thesis will mainly focus on activity of these VTA DA neurons, and its 
main projections. However in addition to the VTA, several minor DA nuclei in the 
ventrolateral periaqueductal grey (vPAG) regions also seem to be involved in the 
reward (Li et al., 2013). This minor DA nucleus, projecting mainly to the BNST, were 
found to be involved in adaptation to social isolation, anxiety, and in adaptations to 
acute cocaine and alcohol exposures (Meloni et al., 2006). 
2.2.3  Afferent control of VTA neurons  
The selective stimulation of different afferent projections to VTA, which became 
possible with the introduction of novel tracing and optogenetic techniques, which 
made it possible to demonstrate that the different excitatory and inhibitory afferent 
inputs to the VTA alter behavior in profoundly different ways by targeting distinct 
DA subpopulations (Lammel et al., 2012; Lammel et al., 2013). In particular, 
activation of glutamatergic projections from the laterodorsal tegmentum (LDT) to 
VTA DA neurons induces burst firing of VTA DA neurons and DA release in NAcc 
lateral shell (Lodge and Grace, 2006; Lammel et al., 2012). This selective stimulation 
of LDT projections elicited rewarding behavior (Lammel et al., 2012). On the other 
hand, stimulation of glutamatergic projections from the lateral habenula to VTA DA 
neurons projecting to the mPFC as well as on VTA GABA neurons in the 
rostromedial tegmental nucleus (also called “tail of VTA”) elicited avoidance 
behavior (Jhou et al., 2009; Stamatakis and Stuber, 2012; Lammel et al., 2012). A 
different approach was taken to examine glutamatergic projections from the ventral 
hippocampus to VTA DA. It has been shown that several different aversive stimuli 
induce robust activation of these glutamatergic projections, which resulted in 
activation of VTA DA neurons (Valenti et al., 2011). Other dense glutamatergic and 
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Figure 3 Main afferents and efferents of VTA involved in reward circuits. Modified from Hikosaka et al., 
2008. 
The activity of VTA is regulated through several systems including dopamine, GABA, glutamate, 
acetylcholine, serotonin, endocannabinoids and orexin. For clarity, many pathways and neuron types 
have been omitted. In dorsal striatum medium spiny neurons expressing dopamine D1 receptors 
marked with red square; expressing D2 receptors with blue square. BLA: basolateral amygdala, BNST: 
bed nucleus of stria terminalis, CeA: central amygdala, DR: dorsal raphe, D-St: dorsal striatum, GPe: 
external segment of globus pallidus, GPi: internal segment of globus pallidus, LH: lateral hypothalamus, 
LHb: lateral habenula, MR: medial raphe, SNc: substantia nigra pars reticulata, SNr: substantia nigra 
pars reticulata, STN: subthalamic nucleus, V-St: ventral striatum, VTA: ventral tegmental area. Filled 
circles indicate inhibitory neurons; open circles indicate excitatory neurons. 
 
  
BNST 
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peptidergic projections come from the lateral hypothalamus (Rosin et al., 2003). Their 
selective stimulation promotes reward by enhancing glutamate transmission in the 
VTA (Kempadoo et al., 2013). 
The bed nucleus stria terminalis (BNST), which integrates stress information in 
the reward system, sends both glutamatergic and GABAergic projections to VTA 
non-DA neurons (Georges and Aston-Jones, 2002; Jalabert et al., 2009; Jennings et 
al., 2013; Kim et al., 2013). Selective optostimulation of glutamatergic BNST 
projections promotes aversive and anxiety-like behavior, whereas stimulation of 
GABAergic BNST projections produce a more complex effect displaying rewarding 
and anxiolytic phenotypes in mice (Jennings et al., 2013). VTA receives other 
gabaergic projection from the ventral pallidum. Recently, this projection to both VTA 
DA and non-DA neurons was found to mediate the effects of opiates (Hjelmstad et 
al., 2013). 
In addition, the activity of VTA is regulated by serotonergic neurons projecting 
from the dorsal raphe (Ferre et al., 1994), by cholinergic neurons from the 
pedunculopontine tegmental nucleus, and laterodorsal tegmental area (Omelchenko 
and Sesack, 2006), as well as endogenous opioids (Kalivas et al., 1993; Hjelmstad et 
al., 2013), noradrenaline (Sara, 2009), orexins (Nakamura et al., 2000), and 
corticotropin-releasing factor (Wanat et al., 2013). 
2.2.4  Diversity of VTA neurons  
Since VTA neurons (Figure 4) obtain such extensive afferent and efferent projections, 
it is not surprising that these neurons are not uniform in nature. In fact, VTA DA 
neurons exhibit distinct electrophysiological, molecular and anatomical properties 
(Margolis et al., 2006; Margolis et al., 2008; Lammel et al., 2013). They also exhibit 
differences in their cellular morphology (Sarti et al., 2007), and in their co-
transmitters such as glutamate and GABA (Chuhma et al., 2004; El Mestikawy et al., 
2011; Tritsch et al., 2012).  
The recent classification of VTA DA neurons was based on the DA projection 
targets, since the majority of these neurons show no overlap in their projections, in 
other words, they follow the rule “one neuron – one target” (Fallon, 1981; Albanese 
and Minciacchi, 1983; Lammel et al., 2013). The combination of retrograde tracing 
and electrophysiology has made it possible to dissect several VTA DA subgroups 
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(Table 3). In particular, VTA DA neurons projecting to the medial shell of NAcc 
selectively respond to the rewarding stimulus. DA neurons projecting to mPFC 
respond only to the aversive (pain) stimulus. In contrast, DA neurons projecting to 
NAcc lateral shell respond to both rewarding and aversive stimuli, evidence that this 
mesocorticolimbic subgroup forms a distinct circuitry, which “may encode the 
occurrence of a salient stimulus independent of its valence” (Lammel et al., 2011).  
 
 
Table 3. Summary of the basal characteristics of the midbrain DA neuron subgroups and response of 
their glutamatergic synapses to rewarding and aversive stimuli. Modified from Lammel et al., 2011.  
 
 
DA subgroups 
  AMPA/NMDA ratio 
Ih-current basal reward aversion 
nigrostriatal present low - - 
mesolimbic lateral shell present low ↑ ↑ 
mesolimbic medial shell absent high ↑↑ - 
mesocortical  absent high - ↑↑ 
 
 
Similar to VTA DA neurons, local GABA interneurons (Figure 4) also can be 
subdivided based on their varying input and output projections (Thierry et al., 1979; 
Kalivas et al., 1993; Omelchenko and Sesack, 2006; Fields et al., 2007; Xia et al., 
2011). In fact, VTA GABA neurons form local contacts into VTA (Omelchenko and 
Sesack, 2006), and also project to the pedunculopontine tegmental nucleus, NAcc and 
PFC (Van Bockstaele and Pickel, 1995; Carr and Sesack, 2000). Furthermore, a 
difference was found in their morphology, physiology and pharmacological properties 
such as the soma’s shape, the presence of Ih-current, durations of action potentials, 
sensitivity to μ-opioid receptor agonists (Chieng et al., 2011; Margolis et al., 2012).  
VTA glutamatergic neurons (Figure 4) were recently discovered in the VTA 
and can be mainly found in the medial VTA (Nair-Roberts et al., 2008; Hnasko et al., 
2012). These neurons appear to send a local excitatory input to both DA and GABA 
neurons (Dobi et al., 2010). VTA glutamate neurons, such as the VTA DA and 
GABA neurons, project to several different brain areas including medial PFC, NAcc, 
lateral habenula, ventral pallidum and amygdala (Hnasko et al., 2012; Yamaguchi et 
al., 2011). 
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Figure 4. Schematic drawing illustrates cell types in the VTA and their distribution. 
A. VTA is composed of dopaminergic (DA), GABAergic (GABA) and glutamatergic (GLU) neurons. B. 
Distribution of EGFP-labeled DA neurons in adult transgenic Th-EGFP mice. Horizontal section of the 
midbrain. Scale bar, 200 μm. 
2.2.5  Synaptic plasticity in VTA DA neurons  
Long-term potentiation (LTP) and depression (LTD) of synaptic strength are believed 
to be the mechanisms that underlie the ability of neural circuits to form memories 
(Malenka and Bear, 2004). Glutamatergic synapses on VTA DA neurons also exhibit 
LTP, and its induction requires NMDA receptor activation and an increase in the Ca2+ 
ion concentration within the postsynaptic dendrite (Chen et al., 2010; Luscher and 
Malenka, 2011). Importantly, alterations in the glutamatergic input onto VTA DA 
neurons have been reported to significantly alter DA release in the terminal brain 
regions that in turn might lead to changes in animal behaviour (Mathon et al., 2003).  
Long-term depression (LTD) also can be triggered in VTA DA neurons. 
Depending on the induction protocol, LTD can occur through several underlying 
mechanisms (Kauer and Malenka, 2007). In particular, LTD can be generated by 
activation of voltage-dependent calcium channels and does not require NMDA 
receptor activation (Jones et al., 2000; Thomas et al., 2000). LTD can also be 
generated by activation of metabotropic glutamate receptors (Bellone and Luscher, 
2006).  
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The increase or decrease in synaptic strengths observed in LTP and LTD, 
respectively, apparently involve regulation of AMPA receptor function and 
trafficking (Kauer and Malenka, 2007). During LTP, additional GluA2-lacking 
AMPA receptors are transported to the cell surface. Importantly, these new receptors 
exhibit some unique properties; first, greater single-channel conductance and, second, 
permeability to Ca2+ ions, which may serve to facilitate Ca2+-dependent signaling 
events (Chen et al., 2010). Conversely, LTD is associated with AMPA receptor 
withdrawal from the cell surface (Hayashi et al., 2000; Bellone and Luscher, 2006; 
Gutlerner et al., 2002). Experimentally, the presence or absence of GluA2-lacking 
AMPA receptors can be determined either electrophysiologically by assessing their 
inward rectification, or pharmacologically by utilizing AMPA subunit–selective 
antagonists (Chen et al., 2010). 
2.2.6  Drug-induced synaptic plasticity in VTA DA neurons  
Drugs of abuse significantly activate DA signaling and increase DA release in the 
NAcc (Luscher and Malenka, 2011). This increase in the extracellular DA 
concentrations is believed to be involved in facilitating learning and memory in brain 
regions innervated by DA (Jay, 2003; Luscher and Malenka, 2011).  
Drugs of abuse short circuit of the brain reward systems so that they “relearn” 
for prioritizing the value of a drug and other vital activities become secondary 
(Luscher and Malenka, 2011). In fact, a single injection of various drugs of abuse is 
already sufficient to induce LTP in glutamatergic synapses on VTA DA neurons, 
which drive spike generation in VTA DA neurons (Saal et al., 2003; Ungless et al., 
2010). Importantly, these drug-induced adaptations appear to be stronger and more 
persistent than those associated with natural rewards (Volkow et al., 1999; Chen et al., 
2008). Many drugs of abuse such as psychostimulants, opioids, alcohol, 
benzodiazepines, and nicotine exhibit different pharmacological effects, but they all 
induce the potentiation of AMPA receptor-mediated synaptic transmission in VTA 
DA neurons (Figure 5) (Liu et al., 2000; Ungless et al., 2001; Saal et al., 2003; 
Borgland et al., 2004; Dong et al., 2004; Chen et al., 2008; Engblom et al., 2008; 
Stuber et al., 2008; Heikkinen et al., 2009). Further studies revealed that cocaine was 
able to disturb both AMPA and NMDA receptor transmission (Mameli et al., 2009). 
LTP observed after a single cocaine injection was transient, but it lasted 
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approximately for 3-5 days (Saal et al., 2003). Notably, chronic treatment with 
cocaine (once/day for 7 days) did not further increase the duration of LTP in VTA DA 
neurons. VTA DA neurons were potentiated for only 5 days (Borgland et al., 2004). 
Thus, regardless of the number of drug injections, LTP at VTA DA neurons persisted 
for days, but still was transient. In addition to the potentiation of glutamatergic 
transmission, these drugs have been found to impair GABAergic transmission in the 
VTA DA neurons, by preventing LTPGABA. In fact, LTP has been reported at fast 
inhibitory GABAA receptor synapses in several brain regions such as the 
hippocampus and visual cortex. This form of LTP of GABAergic synapses (LTPGABA) 
is triggered by NMDA receptor activation at glutamate synapses and requires nitric 
oxide-cGMP signaling (Nugent et al., 2007). Blockade of this LTPGABA could exert an 
additional impact for increased release of DA by silencing local GABA neurons (Liu 
et al., 2000; Melis et al., 2002; Nugent and Kauer, 2008; Niehaus et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
Figure. 5. Schematic of the induction of drug-induced synaptic plasticity in VTA DA neurons. Modified 
from Luscher 2013. 
Drugs of abuse employ distinct cellular mechanisms to cause a redistribution of AMPA- and NMDA- 
receptors in VTA DA neurons. As a consequence, the rules for activity-dependent plasticity are altered, 
and these through yet to be identified signaling pathways evoke adaptive changes in target regions of 
the VTA. Once such adaptive changes have become consolidated, then compulsive behavior becomes 
apparent.  
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2.2.7  Modulation of dopamine system via GABAergic agents  
Since the 1970s, benzodiazepines have been the most commonly used anxiolytic and 
sedative drugs in clinical use (Lalive et al., 2011). They act as positive allosteric 
modulators of γ2-containing GABAA receptors (Hattori et al., 1986; Sigel and 
Luscher, 2011). Targeting of the benzodiazepine binding site on the GABAA receptor 
results in changing the receptor’s conformation that, in turn, enhances the effect of 
GABA. Due to the broad distribution of synaptic γ2-containing GABAA receptors, 
benzodiazepines have a very robust action resulting in several effects that possess 
therapeutic benefits: treatment of insomnia, anxiolysis, treatment of epileptic seizures, 
myorelaxation and anterograde amnesia (Sigel and Luscher, 2011).  
However the situation is not only positive, in long-term use benzodiazepines 
cause tolerance and dependence in many patients. Their addictive properties are still 
poorly understood, but most likely they are at least partly mediated via DA system 
(Heikkinen et al., 2009). Benzodiazepine ligands potentiate glutamatergic 
transmission of VTA DA neurons by silencing local VTA GABA neurons (so called 
disinhibition). In particular, diazepam targets α1-containing GABAA receptors located 
in VTA GABA neurons, and α3-containing GABAA receptors in VTA DA neurons. 
Since GABA neurons appear to be more extensively inhibited, the net effect of 
benzodiazepines will be increased firing of VTA DA neurons (Heikkinen et al., 2009; 
Tan et al., 2010). But it is not known which subtypes of VTA DA and GABA neurons 
mediate this effect.  
Since the α1 subunit has been found to mediate sleep and addiction properties of 
benzodiazepines and also have broad expression over the brain, it has proved 
challenging to develop new sedative benzodiazepines without addictive properties 
(Rudolph and Mohler, 2004; Tan et al., 2010; Lalive et al., 2011). Despite intense 
research over the years, subtype-selective and partial agonists of benzodiazepine-
sensitive GABAA receptors have failed so far (Atack, 2011; Skolnick, 2013). One 
possible solution to this impasse might be seek new drugs targeting the 
benzodiazepine-insensitive extrasynaptic GABAA receptors. These receptors mediate 
tonic inhibition, display selective brain distribution and their activation appears to 
have a milder net effect in comparison to benzodiazepines. The effects of modulators 
of extrasynaptic GABAA receptors on DA reward system should be still clarified.  
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An early in vivo study of agonists of extrasynaptic GABAA receptors revealed 
that muscimol and THIP could dose-dependently increase the firing rates of DA 
neurons (Waszczak et al., 1980). Furthermore, the δ subunit has been found to be 
expressed in VTA and its main targets such as NAcc, mPFC and hippocampus (Pirker 
et al., 2000; Okada et al., 2004; Xiao et al., 2007). New drugs targeting these δ-
containing GABAA receptors are considered to be potential therapeutic benefits for 
several CNS disorders, and several drugs are already under clinical trials. Thus, it is 
clearly important to characterize the effects of these drugs on the DA system. 
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3  AIMS OF THE STUDY 
 
 
 
GABAA receptor-mediated tonic inhibition is considered to be an important inhibitory 
mechanism in the brain. However, the physiological implications of the tonic 
inhibition of the DA reward circuitry are poorly understood. In order to elucidate its 
action on DA neurons, the effects of extrasynaptic GABAA receptor modulators were 
characterized at the cellular and behavioral levels. The aims of this study were as 
follows:  
 
1. To study whether enhanced GABAA receptor-mediated tonic inhibition by 
selective modulators with distinct modes of action could induce 
neuroplasticity in VTA DA neurons, and if so, to clarify underlying cellular 
mechanisms (I, II). 
 
2. To investigate the behavioral significance of the induced synaptic plasticity 
by characterizing reward-related behaviors across the species (I, II). 
 
3. To clarify activation of which brain areas could be involved in THIP-
induced aversive behavioral effects and/or neuroplasticity on VTA DA 
neurons (III). 
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Study II 
 
 
 
 
 
 
 
 
   
 
Study III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. A summary of the main steps involved in studying VTA synaptic plasticity and reward-related 
behaviors after the treatment with gabaxodol (THIP) and ganaxolone (GAN), modulators of 
extrasynaptic GABAA receptors, in studies I-III.   
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4  MATERIALS AND  
METHODS 
 
 
The materials and methods are described in greater detail in the “Materials and 
Methods” sections of the original articles I-III. All experimental procedures were 
approved by the Southern Finland Provincial Government. Only those procedures are 
listed in this chapter where the author was personally involved. All suppliers of drugs 
and equipment are indicated in the original publications and not mentioned here.  
4.1  EXPERIMENTAL ANIMALS 
C57BL/6J mice (Charles River Laboratories), transgenic Th-EGFP (Gong et al., 
2003), GAD67-GFP knockin mice (Tamamaki et al., 2003) and GABAA receptor δ 
subunit-knockout (δ-KO) mice and their wild type littermates (δ-WT) (Mihalek et al., 
1999) were maintained at our facility. Only males were used in the experiments at the 
age of 21-28 days (young mice) or 10-13 weeks (adult mice) unless otherwise 
indicated. The mice were group-housed under a 12-h light/dark cycle with food and 
water available ad libitum.  
4.2  ELECTROPHYSIOLOGICAL STUDIES 
Synaptic responses were measured using a whole-cell patch-clamp technique 
(Sakmann and Neher, 1984). AMPA/NMDA ratio, rectification index and miniature 
AMPA excitatory postsynaptic current (mEPSCs) were applied to elicit long-term 
changes in the efficacy of glutamatergic synaptic transmission (Heikkinen et al., 
2009; Tan et al., 2010). Possible changes in presynaptic function were checked by 
assessing the paired-pulse facilitation ratio (Dobrunz and Stevens, 1997). In the study 
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of the basic properties of GABAA receptor-mediated transmission, GABAergic 
currents were pharmacologically isolated and spontaneous inhibitory postsynaptic 
currents (sIPSC) were recorded (Semyanov et al., 2003).  
4.2.1  Acute midbrain VTA-slice preparation  
Horizontal midbrain slices (225 μm) were obtained from young mice using a vibrating 
blade microtome (Vibratome 1000 plus). After cutting, the slices were allowed to 
recover for 1 h at 37 oC before the recordings were started. 
4.2.2  Identification of the targeted neurons  
In Th-EGFP and GAD67-GFP mice, both VTA DA and GABA neurons were 
visualized using a fluorescence microscope (Olympus BX51WI). In δ-KO and δ-WT 
mice, the DA neurons were identified if a clear Ih-current was observed after voltage 
clamping cells from −70 to −120 mV in 10 mV steps (Heikkinen et al., 2009).  
4.2.3  Electrophysiological recordings and data analysis 
The currents were amplified (Multiclamp 700A), low-pass filtered at 1.6 kHz, and 
digitized at 20 kHz (Molecular Devices). According to protocols, neurons were 
voltage-clamped at a holding potential of -70 mV or +40 mV. The access and 
membrane resistances were monitored throughout the experiment. Recordings were 
discarded if the access resistance changed >20% during the experiment. Recorded 
events were analyzed offline by using ClampFit (pClamp 10) or Mini Analysis 
software (Synaptosoft). 
4.3  BEHAVIORAL STUDIES 
Sedative effect of drugs in the animals was determined by their locomotor activity in 
the open field test. The rewarding profile of the drugs was determined by intravenous 
drug self-administration and place conditioning (conditioned place preference) 
paradigms. The anxiety-related profile of drugs was studied in light-dark exploration 
and open field with new object exploration tests. Acute stress was elicited with a 
modified forced swim task.  
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4.3.1  Locomotor activity of mice 
Mice were placed in the polycarbonate box and allowed to freely explore the activity 
chamber (Heikkinen et al., 2009). Traveled distance was measured automatically by 
Ethovision Color-Pro 3.1 software (Noldus Information Technology). 
4.3.2  Light-dark choice test  
Mice were placed into the lit compartment of the light-dark box apparatus (Med 
Associates). The duration and distance of the movement, number of transitions 
between compartments, the first latency to enter the lit compartment were 
automatically measured by Med Associates software (Crawley and Goodwin, 1980; 
van Rijn et al., 2010). 
4.3.2  Individual exploratory behavior  
The test was subdivided into two parts. Initially, a mouse was placed in the center of 
the open field arena for 3 min and then a yellow plastic ball (new object) was quickly 
installed for another 3 min (Vekovischeva et al., 2013). The duration and distance of 
the movement, the first latency to enter center and contact the new object were 
analyzed subsequently using Ethovision and Ethograph 2.06 software (RITEC).  
4.3.3  Place-conditioning for preference/aversion  
Conditioning took place in two different contexts based on an unbiased paradigm 
(Cunningham et al., 2006). The drug conditioning context was Plexiglas chamber 
with metal grids on the floor whereas the control context was a Plexiglas chamber 
with plastic floor. After 4 conditioning sessions, mice were allowed to choose 
between the above contexts in the test session. Their activity was constantly 
monitored by Ethovision Color-Pro 3.1 software. 
4.3.4  Intravenous drug self-administration in mice 
Mice were tested in pairs, one active and one yoked control, in the individual 
chambers (RITEC). Each chamber had a nose-poking hole equipped with infrared 
sensor. During the “pre-test” session, mice were subsequently paired according to 
their basal nose-poke activity. During the 20-min test, each nose poke of the active 
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mouse resulted in a simultaneous infusion of the same drug through tail vein to both 
active and yoked mice. The reinforcing properties of drugs were then assessed by the 
calculation of the reinforcement factor (Kuzmin et al., 1994). 
4.4  IMMUNOHISTOCHEMICAL STUDIES 
Expression of the immediate early gene c-Fos was chosen as an efficient technique for 
screening of neuronal activation of widespread regions of the brain  (Hughes and 
Dragunow, 1995).  
4.4.1  c-Fos immunohistochemistry  
After drug treatment, brains were dissected, frozen on dry ice and stored at −80oC. 
Immunostaining was performed as described by Procaccini et al. (2011). Fourteen-
μm-thick coronal sections were stained for goat anti- c-Fos antibody (1:800) using 
horse anti-goat secondary antibody (1:200). The c-Fos-immunopositive cells were 
visualised using the avidin–biotin peroxidase complex and diaminobenzidine with 
nickel sulphate intensification.  
Under light microscopy, immunopositive cells were identified by dense black 
nuclear staining in 25 brain areas confirmed by reference to a mouse brain atlas 
(Franklin 2008) with automatic detection of immunopositive cells, constant thresholds 
of light intensity and object size being maintained across all animals within a region 
of interest with Image J software (National Institutes of Health). Four sections per 
mouse for each brain region were counted (observer blinded to the treatment) and 
averaged. 
4.5  STATISTICAL TESTS 
All data were analyzed using GraphPad Prism 5 (GraphPad Software) and PASW 
Statistics 18 (SPSS Inc.). The statistical significance of the differences between 
groups with equal variances was assessed with t-test or analysis of variance 
(ANOVA), followed by post-hoc Bonferroni’s or Dunnett’s tests. Statistical 
significance of the differences between groups with unequal variances was assessed 
with nonparametric Mann-Whitney or Kruskal-Wallis test followed by Dunn’s test.  
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Table 3. Summary of the methods, results and conclusions of studies I-III 
 
Methods Results Conclusions 
 
AMPA/NMDA ratio 
 
 
 
Rectification index 
 
Paired-pulse ratio 
 
 
mEPCSs 
 
 
sIPCSs 
 
 
Place conditioning in 
mice 
 
IV self-administration in 
mice and baboons 
 
THIP (1-3 mg/kg) no effect, THIP (6 
mg/kg) ↑, in δ-KO mice THIP (6 mg/kg) 
no effect in VTA DA cells 
 
THIP (6 mg/kg) ↑ in VTA DA cells 
 
THIP (6 mg/kg) no effect in VTA DA 
cells 
 
↑ frequency after THIP (6 mg/kg) in 
VTA DA cells 
 
↓ frequency after acute THIP (1 μM)  in 
VTA DA cells 
 
THIP (3 mg/kg) no effect, THIP (6 
mg/kg) 
 
THIP no effect 
 
 
THIP induced persistent 
neuroadaptations in VTA DA 
similar to the drugs of abuse. In 
contrast to their reinforcing 
profiles, THIP produced 
persistent aversive place 
conditioning and did not maintain 
self-administration in either mice 
or baboons. We propose that this 
represents a new way of 
modulation of the reward system 
via activation extrasynaptic 
GABAA receptors 
 
AMPA/NMDA ratio 
 
 
 
Rectification index 
 
 
Tonic current 
 
sIPSC 
 
 
Place conditioning in 
mice 
 
GAN (10 mg/kg) no effect, GAN (30 
mg/kg) ↑, in δ-KO mice GAN (30 
mg/kg) no effect in VTA DA cells 
 
GAN (10 mg/kg) no effect, GAN (30 
mg/kg) ↑ in VTA DA cells 
 
GAN (500 nM) ↑ in VTA GABA cells 
 
GAN (500 nM) no effect in VTA DA and 
GABA cells 
 
GAN (30 mg/kg) conditioned place 
aversion, in δ KO mice GAN (30 mg/kg) 
no effect 
 
These findings further support 
the idea of distinct modulation of 
the reward system via 
extrasynaptic receptors. Here, a 
neurosteroid agonist activates 
extrasynaptic GABAA receptors 
via distinct binding site(s) from 
THIP. The neurosteroid induced 
persistent plasticity in the 
excitatory synapses on DA 
neurons via increased tonic 
inhibition of VTA GABA neurons. 
In the behavioral tests GAN 
produced conditioned place 
aversion, but this did not occur in 
GABAA receptor δ-KO mice. 
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c-Fos mapping 
 
 
 
Light-dark choice box 
 
 
Open field with new 
object 
 
Areas activated by THIP (6 mg/kg) in 
young mice: CeM, CeL, PVA; in adult 
mice: BNST 
 
Latency to enter the lit compartment 
after THIP (6 mg/kg) ↑ 
 
Latency to enter the center of arena 
and to contact of new object after THIP 
(6 mg/kg) ↑ 
 
These findings might help to 
dissect specific DA projections 
that are essential for reinforcing 
and aversive behavior. THIP 
elevated the number of c-Fos+ 
cells in the BNST and induced 
anxiety-like behavior in the adult 
mice, evidence that the BNST 
might be involved in mediating 
the aversive effects of THIP 
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 5 RESULTS AND 
 DISCUSSION 
 
 
5.1  THIP AND GANAXOLONE INDUCED 
PERSISTENT LTP OF GLUTAMATERGIC 
SYNAPSES ON VTA DA NEURONS 
(STUDY I, II) 
 
Previous studies had shown that several addictive drugs including benzodiazepines 
selectively evoke a potentiation of glutamatergic currents in VTA DA neurons 
(Ungless et al., 2001; Saal et al., 2003; Heikkinen et al., 2009). This study was 
conducted in order to compare the effects of extrasynaptic GABAA receptor 
modulators with those induced by the synaptic GABAA receptor modulators 
benzodiazepines. Thus, it was decided to use relatively similar doses of THIP and 
ganaxolone based on their sedative effects (Heikkinen et al., 2009). Both modulators 
after a single administration promoted persistent changes of glutamatergic 
transmission which lasted for several days (Table 3). 
5.1.1  THIP and GAN increased AMPA/NMDA receptor-mediated 
current ratio in Th-EGFP mice (I, II) 
 
The direct GABAA receptor agonist THIP (1-6 mg/kg, i.p.) dose-dependently 
increased the AMPA/NMDA ratio in VTA DA neurons measured 24 h after the in 
vivo injection (Study I, Figure 2). The observed effect was similar to that found in 
earlier studies after in vivo administration of ethanol, which was used as a positive 
control (Saal et al., 2003).  
THIP acts at the same binding site as GABA in the interphase of α and β 
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subunits of the GABAA receptors. In contrast, neurosteroids are able to modulate 
GABAA receptors via distinct sites (Hosie et al., 2006), but still retaining a preference 
for the δ subunit-containing receptors. The administration of the synthetic 
neurosteroid ganaxolone (GAN, 10-30 mg/kg, i.p.) resulted in a similar dose-
dependent increase of AMPA/NMDA ratio (Study II, Figure 1). Importantly, both 
THIP and GAN induced plasticity for at least 6 days, while benzodiazepines cause 
this effect for only 3 days (Heikkinen et al, 2009). 
It is noteworthy mentioning that this study used a different approach for 
identification of VTA DA neurons than previously used in the benzodiazepine study 
(Heikkinen et al, 2009). The use of the bacterial artificial chromosome (BAC) Th-
EGFP mouse line made it possible to avoid the complications of DA neuron 
identification via their physiological properties such as the presence of Ih-current 
(Gong et al., 2003; Lammel et al., 2011; Margolis et al., 2008). However, other BAC 
mouse lines that were produced to investigate D1 and D2 DA-receptor expressing 
neurons have recently been reported to display aberrant behavioral responses to 
cocaine (Kramer et al., 2011) and alterations in NAcc synaptic plasticity (Bagetta et 
al., 2012). Thus, concentrations of DA and its metabolites in several brain regions 
were determined in order to ascertain that the present mouse model would not react 
differently to the effects of studied drugs. There were no significant differences in the 
levels of DA or its metabolites in the caudate-putamen/NAcc region and prefrontal 
cortex between the Th-EGFP mice and their littermates without the transgene (Study 
II). Furthermore, additional post hoc analysis of responses of VTA DA neurons 
between several mouse strains (Th-EGFP vs δ-KO) also did not reveal any significant 
differences (Study II).  
In these studies, it was not possible to discern any specific subpopulation (or 
subpopulations) of VTA DA neurons that was (were) activated by these modulators. 
Both THIP and GAN seem to affect several DA populations, which is supported by 
the following two observations. First, mapping of the recorded VTA DA cells 
revealed a homogeneous pattern of activation (Study I, Figure 3). Second, Ih-positive 
and -negative VTA DA neurons, which have been suggested to belong to distinct DA 
subclasses (Lammel et al., 2011), responded to both THIP and GAN in the same 
manner (Study I, II). Further experiments will be needed to establish whether there are 
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specific VTA DA neuron subpopulations (and their afferent inputs) that are affected 
selectively by certain drugs of abuse (Lammel et al., 2011; Fiorillo et al., 2013).   
5.1.2  THIP and GAN were unable to induce glutamate 
neuroplasticity in δ-KO mice  
 
Earlier studies had demonstrated that the δ subunit is required for both THIP and 
GAN effects, but in relation to tonic inhibition, the present results do not completely 
rule out the contribution of other GABAA receptor subtypes, particularly α3 and α5 
subtypes (Mihalek et al., 1999; Uusi-Oukari and Korpi, 2010; Walker and Kullmann, 
2012). These receptors can also sense a low concentration of GABA and can be 
tonically active (Caraiscos et al, 2004; Marowsky et al, 2012). In order to confirm the 
selective action of the drugs on extrasynaptic δ-containing GABAA receptors, the 
experiments were repeated in δ-KO mice, which lack these receptors and the high-
affinity agonist sites (Mihalek et al., 1999; Chandra et al., 2006). Indeed, both THIP 
(Study I, Figure 7) and GAN (Study II, Figure 3) failed to increase the 
AMPA/NMDA ratio in VTA DA neurons 24 h after drug treatment in δ-KO mice. In 
contrast, the δ-WT littermates exhibited a similar glutamate plasticity as observed in 
Th-EGFP mice.  
Although knockout mouse models can be considered as a great tool for 
evaluation of drug selectivity, the gene deletion often leads to compensatory 
mechanisms. In particular, changes in GABAA receptors of δ-KO mice are not limited 
to the loss of the δ subunit in the forebrain. These δ-KO mice have a strong 
upregulation of γ2 and a downregulation of α4, which may complicate the attribution 
of results to the δ-containing GABAA receptors (Korpi et al., 2002; Peng et al., 2002). 
In the present study, one cannot exclude the possibility that the above compensatory 
mechanisms would also take place in the VTA and NAcc. However, the data indicate 
that the δ-KO mice do not show glutamate neuroplasticity after an injection of THIP 
or GAN. These results can be most easily explained by the lack of tonic inhibition 
rather than by a possible compensation via increased synaptic inhibition (which 
actually was not affected in VTA DA or GABA neurons of Th-EGFP by GAN in 
vitro ( Study II, Table 1)).  
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5.1.3  Mechanism of THIP-induced glutamate neuroplasticity. 
Electrophysiological study  
 
To clarify the mechanism underlying the THIP-induced glutamate plasticity, it was 
decided to perform a battery of electrophysiological tests. First, spontaneous 
miniature AMPA receptor-mediated EPSCs (mEPSCs) were recorded in the VTA DA 
neurons at 24 h after the drug treatment to study changes of excitatory transmission of 
VTA DA neurons. THIP (6 mg/kg) increased both amplitudes and frequency of 
events (Study I, Figure 4). This increase of AMPA receptor-mediated transmission 
could reflect either presynaptic or postsynaptic changes such as an increase in the 
number of AMPA receptors or even in the number of synapses.  
In an attempt to distinguish between these scenarios, the paired-pulse ratio in 
the VTA DA neurons was examined to assess the possible presynaptic mechanism of 
long-term plasticity (Mallart and Martin, 1968; Maren and Fanselow, 1995). Since the 
ratio did not differ from control, it was confirmed that no change had occur in the 
probability of neurotransmitter release was confirmed (Study I, Figure 4).  
Therefore, the increase in the amplitude and frequency of AMPA mEPSCs was 
due to some postsynaptic changes. The inward rectification in the I-V relation of 
AMPA receptor EPSCs (so called rectification index test) was then assessed to 
ascertain subunit composition of AMPA receptors. Perturbations in the receptor 
subunitcomposition can have a direct effect on synaptic transmission (see chapter 
2.2.5). If the AMPA receptor lacks GluA2 subunit(s), then it can be blocked by 
intracellular polyamines at positive potentials. Hence, when the neuron is depolarized, 
GluA2-lacking AMPA receptors exhibit their inwardly rectifying property, which 
means that they pass less outward current than inward current (Dingledine et al., 
1999). It was found that THIP treatment induced potentiation in the VTA DA neurons 
through insertion of new GluA2-lacking receptors (Study I, Figure 5), since THIP 
treatment increased the rectification.  
Earlier extensive studies have been carried out to characterize VTA 
neuroplasticity and the mechanisms underlying its induction induced by drugs of 
abuse, particularly by cocaine (Ungless et al., 2001; Borgland et al., 2004; Bellone 
and Luscher, 2006; Mameli et al., 2007; Argilli et al., 2008). Intriguingly, the fact that 
43 
 
the drugs have different molecular targets, and thus distinctive drug-induced behavior, 
similar changes were observed in glutamatergic transmission after a single exposure 
to the drugs.  
Whereas immunocytochemical and in situ hybridization studies demonstrated a 
modest expression of the extrasynaptic GABAA receptors in the VTA (Korpi et al., 
2002; Hortnagl et al., 2013), the heterogeneity of this area complicates the pinpointing 
of possible cellular targets for THIP. Therefore, the acute effect of THIP on the 
inhibitory transmission of VTA DA neurons was evaluated by monitoring their sIPSC 
(Study I, Figure 5). Direct application of THIP led to a net decrease of the total 
inhibitory current in VTA DA neurons. The conclusion from this in vitro experiment 
was that THIP most likely acts on extrasynaptic GABAA receptors present on the 
local GABA neurons, and their resulting silencing seems to be sufficient to cause 
potentiation of DA neurons. These results are consistent with recent findings which 
have demonstrated the presence of functional extrasynaptic GABAA receptors on 
presynaptic GABAergic terminals targeting VTA DA neurons (Xiao et al., 2007).  
In summary, THIP induced persistent changes in glutamatergic transmission of 
VTA DA neurons at least in part through the insertion of new GluA2-lacking AMPA 
receptors. Furthermore, this synaptic plasticity depended on extrasynaptic δ-
containing GABAA receptors within the VTA.  
5.1.4  Tonic inhibition in VTA  
 
Whereas tonic inhibitory currents were presented in both VTA DA and GABA 
neurons (Study II, Figure 2), these tonic currents most likely have a more profound 
inhibitory effect on VTA GABA than DA neurons. Since GABA neurons have a 
higher input resistance, this property allows the same charge transfer to more 
effectively change the membrane potential of GABA neurons than that of DA neurons 
(Margolis et al, 2006; Margolis et al, 2012).  
Both VTA DA and GABA neurons exhibit extensive diversities in the 
magnitude of tonic inhibitory current amplitudes (10-30 pA). Some recorded neurons 
expressed no tonic current. Several explanations of such variation may be outlined: 
first, VTA neurons are heterogeneous with respect to their physiological and 
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pharmacological properties; second, VTA neurons exhibit temporal differences in 
inhibitory transmission. It has been postulated that ambient GABA concentration is 
one of the factors that determine the magnitude of tonic inhibitory currents. The 
concentrations of ambient GABA can vary drastically (from nM to μM range) in 
response to different physiological and experimental conditions (Tossman et al., 
1986; Kennedy et al., 2002). 
All in all, it can be stated that the VTA is a novel brain region which together 
with the hippocampus, cerebellum, cortex, amygdala and thalamic nuclei, whose 
activity can be tuned through additional control of tonic inhibition (Semyanov et al., 
2003; Mody and Pearce, 2004; Marowsky et al., 2012). It is noteworthy that not all 
brain regions that have been inspected exhibit tonic currents under normal conditions. 
For instance, tonic inhibition is normally not observed in hippocampal pyramidal 
neurons in adult rodents (Semyanov et al., 2003; Caraiscos et al., 2004). 
5.1.5  Mechanism of GAN-induced glutamate neuroplasticity. 
Electrophysiological studies  
 
The general pattern of results obtained in experiments with GAN is consistent with 
the findings on the modulation of VTA DA neurons by THIP (Study I). The 
AMPA/NMDA ratio and rectification index tests revealed that GAN induced 
persistent changes of glutamatergic transmission, at least in part via insertion of new 
GluA2-lacking AMPA receptors (Study II, Figure 1).  
Direct application of GAN (500 nM) onto the VTA resulted in a fast and 
selective increase of tonic inhibition in VTA GABA cells (Study II, Figure 2). The 
range of effective neurosteroid concentrations with respect to the prolongation of the 
IPSC event depends on several aspects including local and developmental differences 
(Lambert et al, 2003). For instance, nanomolar concentrations of neurosteroids are 
effective in the cerebellar granule and Purkinje cells, whereas high micromolar 
concentrations of neurosteroids are needed to exert effects in the hypothalamic nuclei 
(Lambert et al, 2003). Even within the same brain region there may be neuronal 
populations with different neurosteroid sensitivities: hippocampal CA1 neurons are 
30-fold more sensitive to neurosteroids than the dentate granule neurons. 
Furthermore, the sensitivity to neurosteroids appears to depend on developmental 
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changes of GABAA receptor subunit composition: younger animals are more sensitive 
to neurosteroids than their adult counterparts (Lambert et al, 2003).  
Next, it was demonstrated that local application of GAN onto VTA was 
sufficient to induce synaptic plasticity in VTA DA neurons. In particular, GAN (500 
nM) caused significantly increased AMPA/NMDA ratios in VTA DA neurons within 
4-6 h, which is consistent with the time frame of the cocaine-induced increase in the 
AMPA/NMDA ratio (Argilli et al., 2008). Thus, this experiment supports local 
mechanisms, but does not exclude the possibility that in vivo drug effects from other 
brain regions could be important for neuroplasticity or behavioral conditioning.  
Taken together with the results in δ-KO mice described above, it is concluded 
that GAN ex vivo induced glutamate receptor neuroplasticity in VTA DA neurons via 
increased tonic inhibition of VTA GABA neurons. These results are in agreement 
with earlier studies demonstrating that allopregnanolone could induce an increase in 
the extracellular DA levels in the NAcc, in a similar manner as muscimol and THIP 
(Kalivas et al., 1990; Rouge-Pont et al., 2002). 
5.2 BEHAVIORAL SIGNIFICANCE OF THE 
SYNAPTIC PLASTICITY INDUCED IN THE 
VTA  
 
The behavioral consequences of THIP- and GAN- induced synaptic plasticity in the 
VTA (or in the brain) were probably one of the most intriguing questions to be 
clarified. Since numerous studies revealed an impact of DA system in encoding drug 
reward, attribution of incentive salience and motivation, it was decided to study 
several reward-related behavioral paradigms, which covered both primary 
unconditioned incentive (reinforcing) and secondary conditioned incentive 
(rewarding) properties of drugs by drug self-administration and conditioned place 
preference (CPP), respectively. 
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5.2.1  THIP exerted no reinforcement, but instead induced 
conditioned aversion in wild-type mice and baboons  
 
Primary rewarding properties of THIP were studied in mice by the intravenous self-
administration protocol based on the yoked-control paradigm (Criswell and Ridings, 
1983). In this test, which is able to evoke a significant self-administration of several 
drugs of abuse (Kuzmin and Zvartau, 1991; Martellotta et al., 1995; Kuzmin and 
Johansson, 2000), no significant differences in rates of self-administration were 
observed in C57BL/6J mice between vehicle and different doses of THIP (0.1-3.0 
mg/ml). Hence, no rewarding properties of THIP were established, in contrast to D-
amphetamine (0.5 mg/ml), which was used as a positive control (Study I, Figure 
8A,B).  
In collaboration with Bjarke Ebert and Nancy Ator, it was possible to 
demonstrate that baboons in a different self-administration paradigm did not 
administer THIP at any studied doses (0.1-1 mg/kg/injection), in contrast they did 
inject the benzodiazepine agonist triazolam (0.01 mg/kg/injection) and cocaine (0.32 
mg/kg/injection) (Study I, Figure 8C). This result offered further evidence that THIP 
does not induce any reinforcement in different species.  
The secondary rewarding properties of THIP was studied by the unbiased 
conditioned place preference (CPP) test. In this test, C57BL/6J mice unexpectedly 
avoided the environment associated earlier with a THIP dose of 6 mg/kg (Study I, 
Figure 9). Moreover, these behavioral results demonstrated correlation with the 
electrophysiological data, since low THIP doses failed to induce glutamate receptor 
plasticity ex vivo and behavioral aversion compared with saline.  
The interpretation of this data requires a degree of caution due the fact that the 
electrophysiological studies (see chapter 5.1) employed young mice, whereas the 
behavioral studies were conducted in adults. This has been done due to several 
methodological reasons. In particular, patch-clamping becomes more challenging in 
adult mice because the neuronal membranes become stiffer, and it is more difficult to 
maintain the long-term stability of the recordings. On the other hand, young mice 
showing higher levels of neuroplasticity can be more sensitive to acute drug effects 
(e.g. Panhelainen et al., 2011), and perhaps react to conditioning differently than 
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adults. CPP in young animals has not been detected in several studies with alcohol, 
amphetamine (Adriani and Laviola, 2003; Song et al., 2007). 
One of the possible explanations for observed conditioned aversion could be the 
fact that THIP treatment could induce absence seizures (also called petit mal seizures) 
(Fariello and Golden, 1987). Typical absence seizures are characterized by a brief 
altered state of consciousness (no longer than 30 s), and they can be detected as 
bilaterally synchronous spike-and-wave discharges in electroencephalography 
(Crunelli and Leresche, 2002). In fact, enhancement of tonic inhibition in 
thalamocortical neurons is known to result in neuronal hyperpolarization, and so a 
change of thalamocortical neuron firing from a regular to a burst pattern, would 
promote the above spike-wave generation. On the other hand, γ-hydroxybutyric acid 
(GHB) has also been found to induce absence seizures, at least in part via δ-
containing GABAA receptors. In contrast to THIP, GHB induces CPP in both mice 
and rats. Future studies using anticonvulsants like ethosuximide to prevent the 
possible induction of these types of seizures during THIP conditioning may be 
informative in this regard. 
It was interesting to evaluate the primary and secondary rewarding properties of 
THIP and to compare them to other reinforcing drugs. Whereas THIP induced 
persistent synaptic plasticity in VTA DA neurons in a same way as benzodiazepines, 
the behavioral consequences of THIP-induced synaptic plasticity were different and 
could be seen as CPA, in contrast to diazepam-induced CPP (Imazumi et al., 2000). 
The distinct VTA intra-circuits seem to express different receptors and thus may 
differently modulate animal behavior. 
5.2.2  GAN induced conditioned aversion in wild-type mice, but not 
in δ-KO mice  
 
The CPP results for GAN were consistent with the findings on THIP (Study I). Once 
again, GAN dose-dependently induce conditioned place aversion (CPA) in C57BL/6J 
mice. In order to examine underlying mechanism of observed GAN-induced CPA, it 
was decided to use the same protocol in δ-KO mice. The lack of δ-containing GABAA 
receptors prevented the induction of conditioned aversion.  
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In the next experiment, the hypothermic effects of GAN and THIP were 
examined to determine whether they might influence performance in the drug-induced 
CPP test. Despite inducing similar CPA, GAN and THIP produced different effects 
on body temperature; THIP had hardly any effects on the core temperature of the 
mice (Study II, Figure 4). Thus, it is reasonable to conclude that hypothermia was not 
responsible for the aversive behavior.  
Interestingly, δ-KO mice responded similarly as their WT littermates, 
suggesting that this hypothermic response was mediated by targets other than δ-
containing GABAA receptors. This conclusion is consistent with a previous study that 
reported no change in ethanol-induced hypothermia in δ-KO mice (Mihalek et al., 
2001). Apparently, the GAN-induced aversion but not its hypothermic effect is 
dependent on δ-subunit-containing GABAA receptors. Hypothermia does not appear 
to be the reason for the aversive conditioning evoked by GAN. 
The interpretation of data obtained from δ-KO mice may have been complicated 
by compensatory adaptations, which could occur in neuronal circuitry during 
development (see 5.1.2). In addition the complete deletion of δ-containing GABAA 
receptors is not able to answer the question of whether δ-containing GABAA receptors 
located within the VTA are responsible for the observed drug-induced synaptic 
plasticity and/or behavior. Therefore, the specific deletion of the δ-containing 
GABAA receptors within VTA for instance by viral-mediated RNAi in adult mice 
would be a potential genetic solution to this problem (Nie et al., 2011). It would also 
be important to perform additional experiments with microinjections of THIP and 
GAN into the VTA or its main targets mPFC/NAcc to clarify the role of the δ-
containing GABAA receptor in GAN-mediated aversion. 
5.3 MECHANISM OF THIP-INDUCED 
GLUTAMATE PLASTICITY. THE c-FOS 
STUDY  
 
To understand which inputs participate in the THIP-induced VTA neuroplasticity and 
following conditioned aversive behavior, it was decided to study activation of 
immediate early gene c-Fos in several brain areas after acute THIP administration. 
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The expression of c-Fos is a nonspecific marker of neuronal activity as c-Fos is often 
expressed in neurons that are firing (Hughes and Dragunow, 1995; Svarnik et al., 
2005). The c-Fos was studied in both young and adult mice in order to clarify earlier 
electrophysiological data obtained in young mice (Study I, II), and behavioral data in 
adult mice (Study I, II). It was found that there was a stronger pattern of c-Fos 
activation in young mice. Particularly, in young mice THIP induced c-Fos activation 
in the central nuclei of amygdala and paraventricular nucleus of thalamus (Study III, 
Figure 1, Table 1), whereas in adult mice THIP induced selective activation of the 
BNST neurons (Study III, Figure 2, Table 1).  
Interestingly, THIP induced a different c-Fos pattern from the modulators of 
synaptic GABAA receptors, benzodiazepines. In articular, sedative doses of diazepam 
are known to induce a distinct activation pattern (Panhelainen and Korpi, 2012), 
which can be explained by the more extensive distribution of synaptic GABAA 
receptors (Pirker et al., 2000). However, it is still possible that THIP may activate 
neurons without turning on c-Fos (Kovacs, 1998). Thus in the future it would be 
important to use additional markers of neuronal activity such as Arc (Link et al., 
1995), and also examine a more detailed time course. 
The BNST, which was selectively activated by THIP, is an important 
connective center between brain stress and reward centers. This region has been 
implicated in the collecting and processing of stress axis information and integrating 
this into the reward/motivation circuitry (Georges and Aston-Jones, 2001; Georges 
and Aston-Jones, 2002; Jennings et al., 2013). The BNST is composed of primarily 
GABAergic neurons (Cullinan et al., 1993), with smaller a contribution of 
glutamatergic neurons (Jalabert et al., 2009). Additionally, neuropeptides such as 
CRF, encephalin, neuropeptide Y, dynorphin, and substance P are present in some 
BNST neurons (Sparta et al., 2013). Thus, in the future, it would be important to 
perform colocalization studies to reveal subtype, receptor, and intracellular signaling 
protein expression of the neurons being activated by THIP treatment. Further by 
taking advantage of novel transgenic c-fos-mRFP1 or Fos/EGFP animal models 
(Fujihara et al., 2009), these THIP-activated neurons could be studied in vitro, for 
instance by patch-clamp and live imaging to characterize signaling pathways, 
electrophysiological properties and drug-induced adaptations within the neurons. In 
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addition, the application of neurotoxins that might selectively “turn off” THIP-
activated cells may be able to clarify the functional importance of THIP-activated 
pathway.  
Probably, the most interesting finding from this study was the behavioral 
validity of THIP-induced BNST activation. It was found that treatment with THIP 
provoked anxiety-like behavior in mice seen in both light-dark choice and open field 
tests (Study III, Figure 3, Table 2), a result consistent with a recent optogenetic study 
demonstrating that BNST-VTA (glutamatergic) projections exhibited a net 
enhancement of firing during an aversive event (Jennings et al., 2013; Kim et al., 
2013). Thus, there is anatomical and behavioral evidence propose a role of BNST in 
the aversive effects of THIP and/or VTA neuroplasticity.  
5.4 AVERSIVE THIP EFFECTS IN ABUSERS. 
ITS LIMITATIONS TO TREAT PRIMARY 
INSOMNIA  
 
Could the present results demonstrating anxiety-like after effects and aversive 
conditioning in THIP-treated mice (Study I,III) be related to aversive THIP effects in 
humans? If this were to be the case, the current battery of behavioural approaches 
(including CPP, anxiety-related tests) might be used in diagnostics to evaluate the 
potential aversive drug properties. In fact, THIP has been noted to provoke 
undesirable feeling of unreality and poor concentration in anxious patients (Hoehn-
Saric et al., 1983). Moreover, THIP at supra-therapeutic doses exhibited certain 
psychiatric side effects in an abuse liability study involving drug abusers. Some of 
these patients experienced feelings such as “euphoria, feeling abnormal, dizziness, 
paresthesia, dissociation, restlessness, and thinking abnormal”, as well as “aversive 
effects like anxiety, fear, headache, nausea, vomiting, and muscle twitching” 
(Schoedel et al., 2009). The mechanisms underlying these aversive THIP effects have 
not yet been identified.  
Regardless of the earlier studies success (Faulhaber et al., 1997; Mathias et al., 
2005; Walsh et al., 2007; Lankford et al., 2008), recent three-month study revealed 
only limited or variable efficacy of THIP [38% of patients on THIP (15 mg) vs 15% 
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of placebo patients] (Roth et al., 2010). Thus, the risk-to-benefit ratio for THIP has 
been too unfavorable to meet the Food and Drug Administration’s (FDA) 
requirements for marketing approval (drugs.com downloaded in November 2013). It 
is still unclear why the drug was ineffective in the above studies. One potential 
explanation may be related to results from a series of in vitro and in vivo studies on 
proton-coupled amino acid transporter (PAT1, Slc36a1). The PAT1 is thought to be a 
transporter that increases the intestinal absorption of THIP (Larsen et al., 2009; 
Larsen et al., 2010). In particular, in view of the control of THIP absorption, is the 
fact that serotonin, tryptamine, 5-hydroxy-L-tryptophan, and sertraline (selective 
serotonin reuptake inhibitor, SSRI, compound used in the clinic to treat depression) 
can drastically diminish absorption of the drug via some unknown indirect mechanism 
(Frolund et al., 2011; Nielsen et al., 2013). Given that compulsive use of the drugs of 
abuse disturb the normal functioning of the serotonergic system, THIP could have had 
an abnormal effect in drug abusers (Kirby et al., 2011). 
A second possibility could arise from transporters through which THIP 
penetrates the BBB. Although there is no available literature on THIP- transporters, 
one of the possible candidates could be the large neutral amino acid transporter type 1 
(LAT1), an important drug transporter (Huwyler and Pardridge, 1998). The human 
LAT1 gene has several single-nucleotide polymorphisms (SNP’s) in the open reading 
frame (e.g. NM_003486). Hypothetically this polymorphism could be envisaged to 
modify the penetration of THIP (i.e. either reducing or increasing BBB penetration) 
leading to variable brain concentrations and different effects between individuals. 
Another possible explanation for the aversive and ineffective THIP treatment 
could arise from differences in food consumption. According to the Food and 
Agriculture Organization of the United Nations, meat consumption (source of amino 
acids) differs between the U.S. and European populations (in 2009: 120 vs 80 
kg/capita/year, http://faostat.fao.org). Intriguingly, nutritionally-relevant mixtures of 
amino acids promote activation of orexin/hypocretine neurons via inhibition of KATP 
channels and activation of system-A amino acid transporters (Venner et al., 2011). 
Since these orexin/hypocretine neurons regulate the sleep-wake cycle, their activation 
might lead to further inhibition of ventrolateral preoptic nucleus (VLPO), the main 
target for THIP in promoting sleep (Lu and Greco, 2006). Thus, this orexin-induced 
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VLPO inhibition might make THIP ineffective in a population consuming a high-
protein diet. Furthermore, orexin neurons directly modulate the mesocorticolimbic 
DA circuit expressing OX1- and OX2- receptors in VTA DA, as well as NAcc and 
mPFC (Borgland and Labouebe, 2010; Yan et al., 2012). There is growing evidence 
indicating that orexin neurons have also been implicated in the pathology of 
psychiatric disorders, including schizophrenia, depression, and addiction. This raises 
the interesting possibility that orexin receptor agonists, which are currently in 
development for the treatment of narcolepsy, may also have some antidepressant-like 
activity (Borgland and Labouebe, 2010). In summary, discovering new molecular 
targets for sedative drugs lacking side effects has proven difficult and it might be 
unrealistic to think that it will be possible to develop preparations suitable for 
everybody. Instead, further development of pharmacogenetics and personalized 
medicine could be one other promising strategy to open up entirely new clinical 
opportunities. 
In conclusion, the experiments presented here have clearly demonstrated the 
obligatory role of extrasynaptic GABAA receptors in the modulation of the 
mesolimbic DA system. By manipulating synaptic activity in the DA system (and/or 
in other neurotransmitter systems) via extrasynaptic stimulation, it may be possible to 
reverse the rewarding effects of addictive drugs. In fact, alcohol intake in rodents has 
been shown to be reduced after treatment with THIP and GAN (Ramaker et al., 2011; 
Ramaker et al., 2012). As well GAN is currently tested as a smoking cessation 
candidate in Phase II (clinicaltrials.gov, NCT01857531). On the other hand, chronic 
treatment with neurosteroids might accelerate development of Alzheimer’s disease in 
several mouse models (Bengtsson et al., 2012; Bengtsson et al., 2013). Moreover, 
reduction of tonic inhibition has been shown to promote functional recovery after 
stroke (Clarkson et al., 2010; Santhakumar et al., 2010). However, studies far beyond 
the scope of this dissertation will be required to understand the true contribution of 
extrasynaptic GABAA receptors and their modulators in the normal and pathological 
function of the brain. Development of new drugs, which can selectively 
activate/inhibit extrasynaptic GABAA receptors, may contribute to the elimination of 
imbalance in tonic GABAergic signaling associated with several pathological 
conditions. 
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 6  CONCLUSIONS 
 
 
 
The results of this study provide some of the first evidence that tonic inhibition plays 
an important role in the modulation of reward dopamine system, and that its 
pharmacological induction leads to persistent neuroadaptations of excitatory 
transmission of VTA DA neurons and conditioned aversive behavior: 
1. Enhanced tonic inhibition by THIP and GAN induces synaptic plasticity of 
glutamate synapses on VTA DA neurons. Despite having distinct modes of action, 
both drugs selectively target δ-containing GABAA receptors located on VTA GABA 
neurons. The tonic inhibition induced in these neurons appears to be sufficient to 
disinhibit DA neurons. The subsequent synaptic plasticity in VTA DA neurons, 
results from insertion of new GluA2-lacking AMPA receptors. 
2. Behaviorally, THIP produced conditioned place aversion in mice, which was 
still evident one month after the last conditioning. Furthermore, THIP failed to induce 
any reinforcement during self-administration in either mice or baboons. GAN, like 
THIP, was able to evoke conditioned place aversion, and this effect was absent in δ-
KO mice. These findings led to the hypothesis that δ-containing GABAA receptors 
mediate aversively conditoned behavior. 
3. The activity of BNST neurons was increased acutely by THIP administration. 
Behaviorally, this could be seen as anxiety-like behavior in adult mice. These findings 
point to a selective set of subcortical nuclei which could take part in THIP-induced 
aversive behavioral effects and/or neuroplasticity on VTA DA neurons. 
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